EP4061386A4 - Procédé de production de cellules t spécifiques multivirus - Google Patents

Procédé de production de cellules t spécifiques multivirus

Info

Publication number
EP4061386A4
EP4061386A4 EP19928301.1A EP19928301A EP4061386A4 EP 4061386 A4 EP4061386 A4 EP 4061386A4 EP 19928301 A EP19928301 A EP 19928301A EP 4061386 A4 EP4061386 A4 EP 4061386A4
Authority
EP
European Patent Office
Prior art keywords
multivirus
cells
producing
specific
producing multivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19928301.1A
Other languages
German (de)
English (en)
Other versions
EP4061386A1 (fr
Inventor
Ercüment Ovali
Gözde Karaku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acibadem Labmed Saglik Hizmetleri AS
Original Assignee
Acibadem Labmed Saglik Hizmetleri AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acibadem Labmed Saglik Hizmetleri AS filed Critical Acibadem Labmed Saglik Hizmetleri AS
Publication of EP4061386A1 publication Critical patent/EP4061386A1/fr
Publication of EP4061386A4 publication Critical patent/EP4061386A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19928301.1A 2019-11-19 2019-12-13 Procédé de production de cellules t spécifiques multivirus Pending EP4061386A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201918044 2019-11-19
PCT/TR2019/051071 WO2021101466A1 (fr) 2019-11-19 2019-12-13 Procédé de production de cellules t spécifiques multivirus

Publications (2)

Publication Number Publication Date
EP4061386A1 EP4061386A1 (fr) 2022-09-28
EP4061386A4 true EP4061386A4 (fr) 2024-01-10

Family

ID=75980745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19928301.1A Pending EP4061386A4 (fr) 2019-11-19 2019-12-13 Procédé de production de cellules t spécifiques multivirus

Country Status (2)

Country Link
EP (1) EP4061386A4 (fr)
WO (1) WO2021101466A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2018052947A1 (fr) * 2016-09-16 2018-03-22 Baylor College Of Medicine Plateforme d'activation et d'expansion de lymphocytes t spécifiques à un virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2018052947A1 (fr) * 2016-09-16 2018-03-22 Baylor College Of Medicine Plateforme d'activation et d'expansion de lymphocytes t spécifiques à un virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
NISHIYAMA-FUJITA YURIKO ET AL: "Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium", CYTOTHERAPY, vol. 20, no. 9, 1 September 2018 (2018-09-01), GB, pages 1182 - 1190, XP093101449, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2018.05.009 *
OMER BILAL ET AL: "Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 622, XP086642640, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V126.23.622.622 *
P. J. HANLEY ET AL: "Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes", BLOOD, vol. 114, no. 9, 27 August 2009 (2009-08-27), pages 1958 - 1967, XP055200362, ISSN: 0006-4971, DOI: 10.1182/blood-2009-03-213256 *
See also references of WO2021101466A1 *
ULRIKE GERDEMANN ET AL: "Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections", MOLECULAR THERAPY, 17 July 2012 (2012-07-17), XP055034394, ISSN: 1525-0016, DOI: 10.1038/mt.2012.130 *
VIJAYENDRA DASARI ET AL: "Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 3, 1 January 2016 (2016-01-01), GB, pages 1 - 9, XP055465882, ISSN: 2329-0501, DOI: 10.1038/mtm.2016.58 *

Also Published As

Publication number Publication date
WO2021101466A1 (fr) 2021-05-27
EP4061386A1 (fr) 2022-09-28

Similar Documents

Publication Publication Date Title
IL276597A (en) A method for producing a low antigenic cell
EP3747996A4 (fr) Procédé de fabrication de cellules
IL280041A (en) A method for producing gamma delta T cells
IL280323A (en) A method for preparing a cd3-positive cell
HUE062863T2 (hu) Eljárás szulfid szilárd elektrolit elõállítására
IL280556A (en) Cell production method
IL291531A (en) A method for activating a cell
EP3842522A4 (fr) Procédé de production de lymphocytes t régulateurs
EP3828252C0 (fr) Procédé de production de biocarburant
EP4053267A4 (fr) Procédé de production de lymphocyte t
IL287063A (en) A method for producing a similar structure-biotissue
SG11202113036WA (en) Process for producing a binder
EP3957600C0 (fr) Procédé de fabrication d'électrolyte solide au sulfure
IL274330A (en) A process for producing a T-cell compound
EP3950942A4 (fr) Procédé de production cellules knock-in
EP3951936A4 (fr) Procédé de fabrication d'élément pour batterie au lithium-ion
EP3882347A4 (fr) Procédé de production de cellules à édition génomique
IL287948A (en) A method for preparing a biocide
PL4004165T3 (pl) Sposób wykonania tabletki paliwowej
EP3993976C0 (fr) Procédé de production d'un élément de construction
PL3940818T3 (pl) Sposób wytwarzania baterii całkowicie w stanie stałym
EP4061386A4 (fr) Procédé de production de cellules t spécifiques multivirus
EP3896155A4 (fr) Procédé de production de cellules à modification génomique
SI3459531T1 (sl) Postopek za proizvodnjo slojevite tablete
GB2589201B (en) Method for producing a water-hydraulic machine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231212

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20231206BHEP

Ipc: C12N 5/00 20060101ALI20231206BHEP

Ipc: A61K 35/17 20150101AFI20231206BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS